Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Estephany Abou Jokh Casas,Nieves Martínez,Urbano Anido Herranz,José Manuel Cabezas-Agrícola,Silvia Varela Ferreiro,Alberto Carral Maseda,Ovidio Fernandez Calvo,José Antonio Mato Mato,Zulema Nogareda Seoane,Sofía Rodríguez Martínez de Llano,Maria Quindós-Varela,F.J. Barón,Omar Rodriguez Fonseca,Antia Cousillas Castiñeira,Gloria Muñiz Garcia,Jose Maria De Matias Leralta,Pablo Fernández Catalina,José Manuel Cameselle Teijeiro,Beatriz Bernardez,Virginia Pubul Núñez

Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2021

364Background: PRRT with 177Lu-Dotatate (Lutathera) is a radiolabeled somatostatin analog indicated treatment of somatostatin receptor (STTR) positive GEP-NETs. The study aims to establish the effi...

Keywords:

radionuclide therapy
peptide receptor
Neuroendocrine tumors
Somatostatin receptor
Somatostatin analog
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations